We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Iqe Plc | IQE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.31 | -3.36% | 8.92 | 16:35:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.40 | 8.98 | 9.64 | 8.92 | 9.23 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Top Posts |
|---|
Posted at 16/4/2025 09:13 by crosswires Sadly a lot has happened since the TU and it’s hard to believe it won’t affect IQEs 2025 earnings, given IQEs past we would be extremely naive to think otherwise. The market is clearly expecting a further earnings hit with our 9p share price and pathetic £90m mc.I expect no growth at the very best in 2025 and it’s how IQE navigates this period via the strategic review to get into shape to resume growth for 2026 that interests me. I feel fairly sure they will need to raise more money somehow, and the favourite was probably the Taiwan sale because I don’t think the market would tolerate another dilutive “raise”. As we know this will be in a much less favourable environment than before Trumps tariff nonsense which is yet another bump in the road that was unexpected at the TU and it wouldn’t surprise me if Taiwan sale is postponed for now. Severe but plausible downside case was outlined in the last results and that seems the likely scenario for this year, but IQE was confident it could pass such a test, let’s hope it’s not even worse than that in reality! IQE are going to need their large shareholders to support them further still through this tough period. Just to add to the joy the Nasdaq futures are down heavily as Trump has restricted Nvidias AI exports which is said to be a $5.5b hit and ASML missed their analyst projections by $1b and ASML's CEO, said tariffs are "creating a new uncertainty" for both the economy and "our potential market demands." In other words chaos but it is what it is. |
Posted at 12/4/2025 12:17 by hannath This is a more in depth description than the release I read mentioning an order from IQE throughout 2025 (albeit not large)Quintessent and IQE Establish Quantum Dot Epitaxial Wafer Supply Chain for AI Optical Interconnects January 23, 2025, 11:00 AM Eastern Standard Time SANTA BARBARA, Calif.--(BUSINESS WIRE)--Quintessent Inc., a pioneer in quantum dot laser technology and heterogeneous silicon photonics, and IQE plc, the leading global supplier of advanced epitaxial wafer products and services, have partnered together to establish the world’s first large-scale quantum dot laser and semiconductor optical amplifier (SOA) epitaxial wafer supply chain. This collaboration, supported by purchase order commitments from Quintessent, will see IQE deliver production quantities of epitaxial wafers to Quintessent throughout 2025. The ever-growing demand for larger parameter models for AI training and inferencing necessitates the interconnectedness of disaggregated compute and memory resources with high bandwidth, low latency, low energy consumption and high reliability, which can only be met with advanced optical interconnects. The laser source within the optical interconnect is a major driver of all these performance metrics, but conventional laser technology and the associated III-V supply chain falls short of AI’s future demands. Reliability of the laser is especially crucial and is perceived to be a limiting factor in scaling optical interconnects for future AI “factories. The supply of high quality and high-volume quantum dot epitaxial wafers for laser sources and SOAs have been limited until recent breakthroughs were achieved by Quintessent and IQE, which have been in the making for the past decade, including research that was spun out of John Bower’s laboratory at the University of California, Santa Barbara. Transitioning the GaAs based quantum dot research to high volume production has resulted in highly optimized and high performing gain material on 6-inch diameter epitaxial wafers that can produce several hundreds of millions of edge-emitting lasers and SOAs per year. “The performance, cost, and reliability advantages that quantum dot-based lasers and amplifiers enable over their quantum well counterparts are exactly what our customers are demanding to address the soaring need for optical connectivity in AI driven compute,” said Alan Liu, CEO and co-founder of Quintessent. “Through our partnership with IQE, we have brought this transformative technology to scale, positioning us to be the leader in delivering solutions leveraging quantum dot laser and SOA technology.” “IQE is very pleased to have received this commitment from Quintessent,” said Mark Furlong, Chief Revenue Officer of IQE. “Our long-term partnership on commercial products and DoD programs has yielded QDL wafers with excellent reproducibility and lasing performance. In addition to expertise in volume manufacturing of epitaxial wafers, our partnership with Quintessent demonstrates IQE's strong track record in scaling the manufacturing readiness of new product into volume production.” About Quintessent Inc.: Quintessent is solving the foundational bottlenecks limiting the scalability and reliability of optical connectivity required by next-generation AI and computing infrastructure. Leveraging multiple innovations that span high-performance quantum dot materials, photonic integrated circuit design, and system-optimized link architecture, Quintessent’s technology slashes power consumption and packaging complexity while achieving multiplicative increases in both bandwidth density and reliability – unlocking the massive scaling needed for future AI applications. Quintessent is headquartered in Santa Barbara, California. To learn more about Quintessent, please visit www.quintessent.com or contact info@quintessent.com About IQE plc: IQE is the leading global supplier of advanced compound semiconductor wafers and materials solutions that enable a diverse range of applications across handset devices, global telecoms infrastructure, connected devices, and 3D sensing. As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in this market which has high barriers to entry. IQE supplies the whole market and is agnostic to the winners and losers at chip and OEM level. By leveraging the Group’s intellectual property portfolio including know-how and patents, it produces epitaxy wafers of superior quality, yield and unit economics. IQE is headquartered in Cardiff UK, with c. 670 employees across nine manufacturing locations in the UK, US, Taiwan and Singapore, and is listed on the AIM Stock Exchange in London. To learn more about IQE, please visit hxxp://iqep.com View source version on businesswire.com: hxxps://www.business Contacts Steven Estrella Direc |
Posted at 11/4/2025 13:57 by guildedge So the T&C. Will IQE be left with a large bill to pay in 12 months if Lombard don't accept the shares?Conversion The Noteholders shall have the right to convert some or all of the principal into ordinary shares at a conversion price of 15 pence per share (the "Conversion Price") at any time prior to maturity of the Loan Notes, and the Company will have the same right provided IQE's daily volume weighted average price of the ordinary shares over both (i) the period of three months; and (ii) the period of seven trading days prior to the date of service of notice of Conversion by the Company exceeds the daily VWAP on the date of issuance of the Loan Notes by more than 33%. In addition if it is the Company serving notice of Conversion, the Noteholders may also elect not to proceed to Conversion for any or all of their Loan Notes and instead be cash-settled. In such circumstances, the Company shall pay the Noteholder: · the nominal value of the Loan Notes, plus · a redemption premium equal to the amount by which the Conversion Price is exceeded by the highest daily VWAP of the Company's ordinary shares over the period of seven trading days prior to the notice of Conversion, multiplied by · the number of the Company's ordinary shares that the Noteholder would have received had it proceeded with Conversion. In the event that the Company redeems the Loan Notes without the Noteholders electing for Conversion or for cash settlement as above, the Company shall issue the Warrants to the Noteholders. The Warrants will allow the Noteholders to subscribe at a price of 15 pence per ordinary share for such number of the Company's shares as would, based on a subscription price of 15 pence, be equal in value to the amount that the Noteholders would have received on redemption of the Loan Notes. The Warrants will lapse and cease to be exercisable if they are not exercised prior to the third anniversary of the date on which the Loan Notes are issued. Adjustments For so long as the Loan Notes remain in issue, the Loan Notes will be subject to adjustment should IQE undertake certain actions that would result in a dilution of the Loan Notes if no adjustment took place. Such actions comprise (i) any allotment or issue of equity securities by IQE; (ii) any cancellation, purchase or redemption, reduction or repayment of equity securities by IQE; and (iii) any sub-division, consolidation or reclassification of IQE's ordinary shares by IQE. The number of and / or the Conversion Price for IQE's ordinary shares to be converted as part of any such adjustment shall be determined and certified by IQE's professional advisors or auditors so that the Noteholders will be entitled to receive the same percentage of the issued share capital of IQE carrying the same proportion of votes exercisable at a general meeting of IQE shareholders and the same entitlement to participate in distributions of IQE, as would have been the case had the Loan Notes not been diluted. |
Posted at 24/3/2025 07:18 by hannath Hopefully will move the share price …IQE plc Cardiff, UK 24 March 2025 IQE secures $5.8m Infrared customer commitments IQE plc (AIM: IQE, "IQE" or the "Group"), the leading global supplier of compound semiconductor wafer products and advanced material solutions, is pleased to announce that it has secured $5.8m in purchase orders for the provision of epitaxial wafers and base substrates from two long-standing Infrared ("IR") sensing customers. The orders will enable a wide range of IR detector technologies and key sensing applications across the industrial, aerospace and security sectors. These commitments are the largest purchase orders to date that IQE has received from these two customers and underscore strong growth within the IR sensing market. They include: · A three-year long-term agreement which includes a first-year binding purchase order commitment of $1.7m for gallium antimonide (GaSb) epitaxial wafers, and research and development. · A $4.1m purchase order from an existing customer for the delivery of antimonide substrates into 2026. These new commitments underpin confidence in management's 2025 financial plans. Jutta Meier, Interim CEO and Chief Financial Officer of IQE, commented: "These commitments underscore a growing demand for advanced infrared technologies and the strength of IQE's IR product portfolio. As a pioneer in antimonide materials technology, IQE continues to drive innovation supported by long-term customer relationships, developing high-performance platforms that are expanding into mass market applications |
Posted at 03/3/2025 09:30 by lord loads of lolly You pays your money & you takes your choice with gross margin. It's all down to adjustments.Key "IQE 2024 gross profit" into Google and it says: IQE plc reported a 25% increase in gross profit from £18.5 million to £23.1 million in the full year ending December 31, 2024. Adjusted gross margins were around 22%. Key "IQE gross margin" into Google and it says: IQE plc's gross profit margin for the last 12 months was 8.9%. Problem is IQE incurs costs & invests money in year 1 for something that won't generate any revenue before year 2 or 3. Theory is adjusted figures better represent this time lag, though in practice it hasn't always worked out that way (e.g. if capex investment doesn't ultimately bear fruit in terms of increased sales & profit). |
Posted at 14/2/2025 14:32 by lord loads of lolly gnnmartin - this loan note financing sure is complex!I'm no expert, but in essence the way I read it is: it cost IQE £3.176m to issue the loan notes (i.e. £21,176,470.59 to raise £18 million net). The initial term of these notes is 12 months. Noteholders can convert their notes to shares at 15p per share at any time before maturity. I'm unclear whether the Volume Weighted Average Price (VWAP) of IQE's shares has to exceed 33% over three months and again over the seven trading days pre-conversion in order to trigger conversion. Or whether this only applies if it's IQE doing the triggering. Anyone know the answer to this? If the note conversion is triggered, noteholders can decide to take cash, rather than the 15p shares. In which case, they'd get 15p per loan note PLUS the amount by which 15p is exceeded by the highest daily VWAP of the shares over the 7 trading days pre-conversion, multiplied by the number of shares the noteholder would have received if they'd converted. As you mention, the loan notes can be extended by a further 6 months. In which case, on redemption, IQE pays the noteholders the nominal value of the loan notes, plus a 9% premium on each loan note. It strikes me as an expensive way to raise money for IQE and far more of a win-win for noteholders than shareholders (particularly as the notes are "secured against the Company's assets in the UK and subordinated to the Company's existing financing facility with HSBC". Hope this helps. A bit at least! |
Posted at 14/2/2025 08:51 by crosswires It was C, actual news in the form of an RNS always motivates or spooks some investors and also drives the MM’s to some extent. It’s all a game and it will play out according to how IQE can perform in these areas over the next 12 months. One thing is for certain the chart will be irrelevant, it and the share price will be reliant by news flow not candles and the like.1. Taiwan. Can IQE release significant value from their Taiwan concern via a successful IPO. It’s not a given and listing isn’t cheap. 2. CEO appointments. IQE need an adult, and must find the right balance of industry savvy and business acumen. Sure it’s important to have a vision, but only if it’s based in reality not some space cadet notion of 3x revenue in short term. Adults need only apply. 3. Market demand. Will the semi cycle fall more favourably for IQE, with a wide recovery and with particular regards to GaN. Oversupply needs to disappear for IQE to get back towards and above £150m revenue again. 4. News flow. Over the last few years we have mainly only seen negative RNS’. If we wake up to some unexpectedly positive releases for a change which signal new business or significant increases in current contracts. Partnerships based on technology that may never be commercial or are years away from large revenue won’t count. |
Posted at 12/2/2025 07:17 by a13878713 Cardiff, UK12 February 2025 Convertible Loan Note FinancingIQE plc (AIM: IQE, "IQE" or the "Company"), one of the leading global suppliers of compound semiconductor wafer products and advanced material solutions, is pleased to announce that, further to the announcement of 18 November 2024, it has entered into subscription agreements with a consortium of existing investors and certain senior executives and Directors, led by its largest shareholder Lombard Odier[1] (the "Noteholders").Under the terms of the subscription agreements, the Noteholders have conditionally agreed to subscribe for, and IQE has conditionally agreed to issue, secured zero-coupon convertible loan notes with a conversion price of 15 pence per ordinary share in the Company pursuant to a convertible loan note instrument (the "CLN") (the "Loan Notes") at 85% of the Loan Notes' face value to raise aggregate subscription proceeds for IQE of £18 million (the "Proposed Transaction"). The initial term of the Loan Notes is 12 months, with an option to extend the Loan Notes for a further six months. Full details of the subscription agreements and CLN are set out below at Appendix 1.The CLN will be secured against the Company's assets in the UK and subordinated to the Company's existing financing facility with HSBC UK Bank PLC ("HSBC") which will be amended and restated upon issuance of the Loan Notes. The directors do not expect the need to raise near term capital following the completion of the Proposed Transaction.No offer or invitation is being made to shareholders more generally to purchase, acquire or subscribe for any of the Loan Notes (as defined below). No application will be made for the admission of the Loan Notes to trading on AIM or any recognised securities exchange. General MeetingThe issuance of the Loan Notes, and therefore the Proposed Transaction is conditional, inter alia, on the passing of resolutions by shareholders (the "Resolutions") at a general meeting of IQE (the "General Meeting"). IQE will shortly send a circular (the "Circular") and a notice convening the General Meeting. The Circular includes, inter alia, details of the CLN and the Resolutions, which are being proposed (a) by way of ordinary resolution, to approve the directors' authority to allot ordinary shares with an aggregate nominal value of up to £1,538,823.53, being equal to 153,882,353 new ordinary shares over which rights to subscribe are being granted by the Company pursuant to the issuance of the Loan Notes and, in the event that the conversion of the principal amount of the Loan Notes into new ordinary shares (the "Conversion") does not take place, warrants to subscribe for ordinary shares (the "Warrants"); and (b) by way of special resolution, to empower the directors to allot and issue equity securities for cash on a non-pre-emptive basis with an aggregate nominal value of up to £1,538,823.53, being equal to 153,882,353 new ordinary shares over which rights to subscribe are being granted by the Company pursuant to the issuance of the Loan Notes and, in the event that Conversion does not take place, the Warrants.As previously announced, the Company is undertaking a Strategic Review which the directors believe will unlock significant unrealised value within the IQE group. The Proposed Transaction is integral to the Strategic Review and the Company's ability to demonstrate financial resilience to both our customers and potential parties to the Strategic Review. Shareholders should be aware that if the Resolutions are not approved at the General Meeting, the Proposed Transaction cannot complete and IQE will not receive the net proceeds from the issuance of the Loan Notes. The directors of IQE independent of the Proposed Transaction, believe that successful completion of the Proposed Transaction is required to maintain sufficient short-term liquidity whilst the Company completes the ongoing strategic review. |
Posted at 23/1/2025 07:21 by samed1 cTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). Cardiff, UK23 January 2025 Pre-close Trading Update - FY24 revenue and Adj. EBITDA expected to exceed expectations- Positive impact of cost actions evidenced IQE plc (AIM: IQE, "IQE" or the "Group"), the leading global supplier of compound semiconductor wafer products and advanced material solutions, provides a pre-close Trading Update for the financial year ended 31 December 2024.Revenue for the period is expected to be at £118m, combined with focused cost control and improved operational performance, the Group expects Adjusted EBITDA to be at least £7.5m, exceeding expectations* and subject to external review. Strategic review and Proposed FinancingAs announced in November 2024, IQE is undertaking a Strategic Review which the Board believes will better unlock significant unrealised value within the Group. At this stage, the strategic review is focused on its Taiwan operations covering all strategic options, including IPO or a full sale. While the review remains at an early stage, the Board is encouraged by the positive levels of interest from its partners and the broader recognition that the Group is a technical leader across a variety of strategically important vertical markets, with a well-invested asset base.In addition, the Group is pleased to say it is in the final stages of concluding its proposed convertible loan note and that it has received strong support from shareholders. This process is expected to conclude shortly and an announcement will be made accordingly. A circular will be sent to shareholders providing further details and seeking their approval in due course. Mark Cubitt, Executive Chair of IQE, commented:"I am pleased that the business performance in 2024 will show revenue and adjusted EBITDA ahead of expectations. Amid ongoing macro headwinds, Jutta and the leadership team have taken effective action to refocus the Group on its core strengths and improve operational performance, resulting in an encouraging financial picture. I am really pleased by the reaction from our staff, customers and shareholders to the announcement of the strategic review, and the resulting positive engagement. In addition, the proposed financing will provide IQE with greater resilience as we continue to strengthen key customer relationships and expand further into emerging high growth areas"*As communicated on 18 November 2024, the group expected revenue to be around £115m and Adjusted EBITDA of at least £5m for the financial year ended 31 December 2024. Contacts: IQE plc+44 (0) 29 2083 9400Mark CubittJutta MeierAmy Barlow |
Posted at 04/12/2024 07:14 by a13878713 IQE plcCardiff, UK4 December 2024IQE announces completion of Pennsylvania site sale processas part of global consolidation strategyIQE plc (AIM: IQE, "IQE" or the "Group"), the leading supplier of advanced compound semiconductor wafer products and material solutions to the global semiconductor industry, today announces that it has completed the sale of its decommissioned site in Bethlehem, Pennsylvania. As a result of the sale, IQE will receive $2.5m immediately and a further $3.0m before the end of the year.IQE ceased operations in the Pennsylvania site in late 2023 and has since transferred the site's expertise, IP, assets and customers to its larger facility in Greensboro, North Carolina. This has allowed IQE to concentrate its efforts in North America on developing this site into a world-class facility serving advanced sensing, optical communications, aerospace & defence and wireless markets. The North Carolina site is also supported through significant funding from the local government.Jutta Meier, Interim CEO and CFO, commented:"The completion of the sale of our decommissioned Pennsylvania site will further strengthen our balance sheet, bringing in $5.5m in cash by the end of 2024. I am pleased to complete this milestone and the further consolidation of our manufacturing footprint. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
